Gastric Cancer Clinical Trials in Columbus, Ohio

7 studies are recruiting for gastric cancer in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Columbus, Ohio

   Locations

   311 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

2. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Columbus, Ohio

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

3. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University, Columbus, Ohio

   Locations

   54 in total

   Run by

   Merus B.V.

   See if you can join NCT03526835 on ClinicalTrials.gov

4. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Ohio State University, Columbus, Ohio

   Locations

   11 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

5. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

6. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

   This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   6 in total

   Run by

   Tanabe Pharma America, Inc.

   See if you can join NCT06943521 on ClinicalTrials.gov

7. Comprehensive Outcomes for After Cancer Health

   This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

   Stage

   Not phased

   Ages

   18 and older

   Site

   The Ohio State University Wexner Medical Center, Columbus, Ohio

   Locations

   7 in total

   Run by

   Pack Health

   See if you can join NCT05349227 on ClinicalTrials.gov